Inventiva Pharma

Update in progress

IVA (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for metabolic and fibrotic diseases. It develops Lanifibranor, a pan-PPAR agonist in NATiV3 Phase 3 for MASH; Odiparcil for mucopolysaccharidoses; and a preclinical TGF-β program for idiopathic pulmonary fibrosis. Founded in 2011, the company is headquartered in Daix, France, with international activity.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive